Shares of Lantheus Holdings (NASDAQ: LNTH) soared 5.15% in pre-market trading on Wednesday, following the company's strong fourth-quarter 2024 financial results and upbeat outlook for the year ahead.
The radiopharmaceutical company reported a 10.5% year-over-year increase in revenue to $391.1 million for the fourth quarter, exceeding analysts' expectations of $377.1 million. Adjusted earnings per share (EPS) came in at $1.59, surpassing the consensus estimate of $1.54.
Lantheus' blockbuster radiodiagnostic product, PYLARIFY, continued to drive growth, with sales reaching $1.06 billion for the full year 2024, marking a significant milestone as the first radiodiagnostic to achieve blockbuster status.
For the full year 2025, the company provided revenue guidance in the range of $1.545 billion to $1.61 billion, slightly below analysts' expectations of $1.605 billion. However, Lantheus' adjusted EPS guidance of $7.00 to $7.20 exceeded the consensus estimate of $6.95.
Lantheus also highlighted its strategic initiatives to enhance its radiopharmaceutical leadership, including the acquisition of Life Molecular Imaging Ltd. and Evergreen Theragnostics Inc. These acquisitions are expected to diversify the company's portfolio and expand its pipeline with late-stage and early-stage assets.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。